abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Report

5 Jan 2015

Author:
Médecins Sans Frontières

Full briefing

See all tags

"Barriers to Access and Scale up of Hepatitis C (HCV) Treatment: Gilead’s Anti–Diversion Program, MSF Briefing Document, January 2015"

...MSF has learned that the company will institute an ‘anti-diversion’ programme in developing countries through its distributors and licensees…  to prevent what they characterize as the possible ‘bulk diversion’ or re-sale of such medicines…  Gilead’s programme violates patient privacy and autonomy...

Read the full briefing here

Timeline